Back

Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines

2023-08-24 infectious diseases Title + abstract only
View on medRxiv
Show abstract

BackgroundSubvariants of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) omicron XBB-lineage have the potential to escape immunity provided by prior infection or vaccination. For Covid-19 immunizations beginning in the Fall 2023, the U.S. FDA has recommended updating to a monovalent omicron XBB.1.5-containing vaccine. MethodsIn this ongoing, phase 2/3 study participants were randomized 1:1 to receive 50-{micro}g doses of mRNA-1273.815 monovalent (50-{micro}g omicron XBB.1.5 spike...

Predicted journal destinations